These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 26521928)

  • 1. Efficient strategy for obtaining reliable pharmacokinetic parameters in population compartmental approaches.
    Lee J; Kang D; Kim E; Kim BH
    Int J Clin Pharmacol Ther; 2016 Jan; 54(1):11-8. PubMed ID: 26521928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
    Mu S; Ludden TM
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic analysis of pegylated human erythropoietin in rats.
    Jolling K; Ruixo JJ; Hemeryck A; Piotrovskij V; Greway T
    J Pharm Sci; 2004 Dec; 93(12):3027-38. PubMed ID: 15503315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic parameters estimation using adaptive Bayesian P-splines models.
    Jullion A; Lambert P; Beck B; Vandenhende F
    Pharm Stat; 2009; 8(2):98-112. PubMed ID: 18481279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
    Plock N; Facius A; Hartmann L; Baumann S; Nave R
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):495-508. PubMed ID: 23611571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population one-compartment pharmacokinetic analysis with missing dosage data.
    Soy D; Beal SL; Sheiner LB
    Clin Pharmacol Ther; 2004 Nov; 76(5):441-51. PubMed ID: 15536459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of sparse data sampling on population pharmacokinetics: a post hoc analysis of a pharmacokinetic study of morphine in healthy volunteers.
    Ariano RE; Duke PC; Sitar DS
    Clin Ther; 2012 Mar; 34(3):668-76. PubMed ID: 22381713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pragmatic approach to the design of population pharmacokinetic studies.
    Roy A; Ette EI
    AAPS J; 2005 Oct; 7(2):E408-20. PubMed ID: 16353920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin.
    Jolling K; Perez Ruixo JJ; Hemeryck A; Vermeulen A; Greway T
    Eur J Pharm Sci; 2005 Apr; 24(5):465-75. PubMed ID: 15784336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modeling.
    Jaber MM; Brundage RC
    J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):123-132. PubMed ID: 36617366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data.
    Yang S; Roger J
    Pharm Stat; 2010; 9(4):313-30. PubMed ID: 20043295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine].
    Zuo XC; Yuan H; Zhang BK; Ng CM; Barrett JS; Yang GP; Huang ZJ; Pei Q; Guo R; Zhou YN; Jing NN; Di W
    Yao Xue Xue Bao; 2012 Jul; 47(7):941-6. PubMed ID: 22993862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis.
    Anderson BJ; Pons G; Autret-Leca E; Allegaert K; Boccard E
    Paediatr Anaesth; 2005 Apr; 15(4):282-92. PubMed ID: 15787918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study.
    Kowalski KG; Hutmacher MM
    Stat Med; 2001 Jan; 20(1):75-91. PubMed ID: 11135349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations in analyzing single-trough concentrations using mixed-effects modeling.
    Booth BP; Gobburu JV
    J Clin Pharmacol; 2003 Dec; 43(12):1307-15. PubMed ID: 14615466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.